CN114167051B - 一种化学发光免疫微球冻干制剂及其制备方法以及应用 - Google Patents
一种化学发光免疫微球冻干制剂及其制备方法以及应用 Download PDFInfo
- Publication number
- CN114167051B CN114167051B CN202111553600.7A CN202111553600A CN114167051B CN 114167051 B CN114167051 B CN 114167051B CN 202111553600 A CN202111553600 A CN 202111553600A CN 114167051 B CN114167051 B CN 114167051B
- Authority
- CN
- China
- Prior art keywords
- preparation
- freeze
- percent
- detection
- microsphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 99
- 239000004005 microsphere Substances 0.000 title claims abstract description 67
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 54
- 239000002994 raw material Substances 0.000 claims abstract description 31
- 239000006249 magnetic particle Substances 0.000 claims abstract description 23
- 238000002372 labelling Methods 0.000 claims abstract description 18
- 239000011232 storage material Substances 0.000 claims abstract description 18
- 238000000576 coating method Methods 0.000 claims abstract description 16
- 239000011248 coating agent Substances 0.000 claims abstract description 15
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims abstract description 12
- 239000002245 particle Substances 0.000 claims abstract description 10
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 238000004108 freeze drying Methods 0.000 claims description 14
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 8
- 239000005018 casein Substances 0.000 claims description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 8
- 235000021240 caseins Nutrition 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 239000003223 protective agent Substances 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 72
- 210000002966 serum Anatomy 0.000 abstract description 23
- 239000000203 mixture Substances 0.000 abstract description 18
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 abstract description 15
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 abstract description 15
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 abstract description 15
- 108010048233 Procalcitonin Proteins 0.000 abstract description 13
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 abstract description 13
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical group C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 abstract description 9
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 abstract description 8
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 abstract description 8
- 239000002243 precursor Substances 0.000 abstract description 8
- 102000011923 Thyrotropin Human genes 0.000 abstract description 7
- 108010061174 Thyrotropin Proteins 0.000 abstract description 7
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 238000004806 packaging method and process Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 102000007066 Prostate-Specific Antigen Human genes 0.000 abstract description 5
- 108010072866 Prostate-Specific Antigen Proteins 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 4
- 230000001900 immune effect Effects 0.000 abstract description 3
- 238000003908 quality control method Methods 0.000 description 36
- 239000011324 bead Substances 0.000 description 21
- 239000007788 liquid Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 102400001263 NT-proBNP Human genes 0.000 description 15
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000005284 excitation Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000004020 luminiscence type Methods 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000007710 freezing Methods 0.000 description 7
- 230000008014 freezing Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000013112 stability test Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 230000008105 immune reaction Effects 0.000 description 5
- 210000001685 thyroid gland Anatomy 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- -1 acridine ester Chemical class 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000013394 Troponin I Human genes 0.000 description 3
- 108010065729 Troponin I Proteins 0.000 description 3
- BDQRMEBGHYKVLA-UHFFFAOYSA-N acridine-1-sulfonamide Chemical compound C1=CC=C2C=C3C(S(=O)(=O)N)=CC=CC3=NC2=C1 BDQRMEBGHYKVLA-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 238000009777 vacuum freeze-drying Methods 0.000 description 3
- KQFCNGKUXYNDPF-UHFFFAOYSA-N 3-[9-[[4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutyl]-(4-methylphenyl)sulfonylcarbamoyl]acridin-10-ium-10-yl]propane-1-sulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N(C(=O)C=1C2=CC=CC=C2[N+](CCCS([O-])(=O)=O)=C2C=CC=CC2=1)CCCC(=O)ON1C(=O)CCC1=O KQFCNGKUXYNDPF-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960000874 thyrotropin Drugs 0.000 description 2
- 230000001748 thyrotropin Effects 0.000 description 2
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- WBLZUCOIBUDNBV-UHFFFAOYSA-N 3-nitropropanoic acid Chemical compound OC(=O)CC[N+]([O-])=O WBLZUCOIBUDNBV-UHFFFAOYSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102100036836 Natriuretic peptides B Human genes 0.000 description 1
- 101710187802 Natriuretic peptides B Proteins 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 206010053260 Secondary hyperthyroidism Diseases 0.000 description 1
- 206010039840 Secondary hypothyroidism Diseases 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000029305 central congenital hypothyroidism Diseases 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
检测次数 | 1 | 2 | 3 | 4 | 5 |
1000pmol/mL | 73626 | 72913 | 74183 | 72095 | 73037 |
10000pmol/mL | 630022 | 667873 | 686925 | 664219 | 681297 |
检测次数 | 6 | 7 | 8 | 9 | 10 |
1000pmol/mL | 65973 | 74857.5 | 76473 | 74227.5 | 66450 |
10000pmol/mL | 638059 | 692938 | 667815 | 659324 | 646513 |
交叉反应物质 | 交叉反应物质浓度 | 交叉反应物质测定值 |
人血清白蛋白 | 12g/dL | 9.5pmol/mL |
甘油三酯 | 3000mg/dL | 0.5pmol/mL |
血红素 | 500mg/dL | 15pmol/mL |
胆红素 | 20mg/dL | 5pmol/mL |
BNP | 3000ng/mL | 19.5pmol/mL |
低值质控 | 25126 | 24185 | 26060 | 27564 | 25617 | 24960 | 27199 | 25888 |
中值质控 | 112027 | 111944 | 110999 | 112185 | 112605 | 110255 | 115410 | 110706 |
高值质控 | 2659771 | 2757514 | 2761693 | 2604084 | 2846512 | 2779399 | 2646242 | 2677880 |
低值质控 | 1716 | 1804 | 1722 | 1903 | 1670 | 1778 | 1735 | 1843 | 1971 | 1901 |
中值质控 | 81609 | 82423 | 79423 | 72391 | 82955 | 81894 | 75430 | 79957 | 83744 | 82339 |
高值质控 | 1375719 | 1420326 | 1301410 | 1353346 | 1402974 | 1324529 | 1429669 | 1396950 | 1443193 | 1390767 |
低值质控 | 5127 | 4911 | 5070 | 4860 | 4655 | 5035 | 5190 | 4749 | 5181 | 5173 |
中值质控 | 211402 | 230576 | 228395 | 236551 | 215328 | 219196 | 221059 | 213846 | 225576 | 222456 |
高值质控 | 3000248 | 3150949 | 2999042 | 2890001 | 2957357 | 3085279 | 2682852 | 3239993 | 3118219 | 3113297 |
低值质控 | 9708 | 9331 | 8786 | 9275 | 10726 | 8901 | 8737 | 8909 | 9359 | 8700 |
中值质控 | 678348 | 677059 | 668200 | 674786 | 657789 | 649892 | 669875 | 677440 | 680303 | 681485 |
高值质控 | 12865474 | 13165513 | 12612679 | 12604284 | 12457846 | 12760793 | 12740510 | 12806635 | 12622764 | 12244357 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/965,761 US20230048869A1 (en) | 2020-12-18 | 2022-10-13 | Freeze-dried preparation of chemiluminescent immune microspheres, and preparation method and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020115006805 | 2020-12-18 | ||
CN202011500680.5A CN112684167A (zh) | 2020-12-18 | 2020-12-18 | 一种化学发光免疫试剂、冻干微球及其及冻干微球的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114167051A CN114167051A (zh) | 2022-03-11 |
CN114167051B true CN114167051B (zh) | 2024-04-05 |
Family
ID=75448989
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011500680.5A Pending CN112684167A (zh) | 2020-12-18 | 2020-12-18 | 一种化学发光免疫试剂、冻干微球及其及冻干微球的制备方法 |
CN202111553600.7A Active CN114167051B (zh) | 2020-12-18 | 2021-12-17 | 一种化学发光免疫微球冻干制剂及其制备方法以及应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011500680.5A Pending CN112684167A (zh) | 2020-12-18 | 2020-12-18 | 一种化学发光免疫试剂、冻干微球及其及冻干微球的制备方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230048869A1 (zh) |
EP (1) | EP4124863A4 (zh) |
CN (2) | CN112684167A (zh) |
WO (1) | WO2022127135A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112684167A (zh) * | 2020-12-18 | 2021-04-20 | 安邦(厦门)生物科技有限公司 | 一种化学发光免疫试剂、冻干微球及其及冻干微球的制备方法 |
CN114152739A (zh) * | 2021-12-08 | 2022-03-08 | 江西赛基生物技术有限公司 | 荧光抗体冻干小球及其制备方法 |
CN114167049A (zh) * | 2021-12-08 | 2022-03-11 | 江西赛基生物技术有限公司 | 冻干小球及其制备方法 |
CN114480591B (zh) * | 2022-03-09 | 2022-11-08 | 武汉爱博泰克生物科技有限公司 | 一种用于一步法qpcr试剂的冻干保护剂及其应用 |
CN117159480B (zh) * | 2023-11-01 | 2024-03-01 | 江西赛基生物技术有限公司 | 一种重组人IFN-γ蛋白冻干小球及其制备方法和应用 |
CN118091117B (zh) * | 2024-04-25 | 2024-07-02 | 江西赛基生物技术有限公司 | 一种用于制备冻干小球的保护剂及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198717A (zh) * | 2014-08-30 | 2014-12-10 | 中国科学院苏州生物医学工程技术研究所 | 一种浓缩葡萄糖检测试剂冻干微球及其制备方法 |
CN110988367A (zh) * | 2019-11-18 | 2020-04-10 | 迈克生物股份有限公司 | 一种贮存剂、用于检测lh的校准品及检测试剂盒 |
CN111965344A (zh) * | 2020-08-25 | 2020-11-20 | 沈阳瑞好生物科技有限公司 | 一种冻干磁微粒化学发光免疫检测试剂盒及其制备方法 |
CN112684167A (zh) * | 2020-12-18 | 2021-04-20 | 安邦(厦门)生物科技有限公司 | 一种化学发光免疫试剂、冻干微球及其及冻干微球的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08233820A (ja) * | 1995-02-23 | 1996-09-13 | Kdk Corp | 化学発光測定法 |
US20050069898A1 (en) * | 2003-09-25 | 2005-03-31 | Cepheid | Lyophilized beads containing mannitol |
EP1970705A1 (en) * | 2007-03-15 | 2008-09-17 | Koninklijke Philips Electronics N.V. | Bead assisted analyte detection |
US20100168018A1 (en) * | 2008-11-07 | 2010-07-01 | Baxter International Inc. | Factor viii formulations |
CN101893627B (zh) * | 2010-07-08 | 2014-12-17 | 崔亚丽 | 金磁微粒标记免疫层析快速检测方法 |
JP6107129B2 (ja) * | 2012-12-27 | 2017-04-05 | 東ソー株式会社 | 生体物質固定化微粒子の製造方法 |
CN104215753B (zh) * | 2014-08-30 | 2016-06-22 | 中国科学院苏州生物医学工程技术研究所 | 一种浓缩二氧化碳结合力检测试剂冻干微球及其制备方法 |
CN107397725A (zh) * | 2016-05-20 | 2017-11-28 | 重庆润泽医药有限公司 | 注射用左旋奥拉西坦冻干组合物及其制备方法 |
CN106226526A (zh) * | 2016-06-30 | 2016-12-14 | 深圳市亚辉龙生物科技股份有限公司 | 一种锌转运蛋白8抗体化学发光免疫检测试剂盒及其制备方法 |
AU2018306303A1 (en) * | 2017-07-25 | 2020-02-20 | Elektrofi, Inc. | Formation of particles including agents |
CN107281481B (zh) * | 2017-08-02 | 2020-10-09 | 华派生物工程集团有限公司 | 一种伪狂犬活疫苗耐热冻干保护剂、制备方法和冻干疫苗及制备方法 |
CN108008125A (zh) * | 2017-12-18 | 2018-05-08 | 江苏浩欧博生物医药股份有限公司 | 一种适用于免疫磁珠的冻干工作液和免疫磁珠冻干品及其制备方法 |
CN110954699A (zh) * | 2019-12-11 | 2020-04-03 | 北京柏兆嘉业科技有限公司 | 一种微流控盘及使用该微流控盘进行检测的方法 |
CN111665352B (zh) * | 2020-06-23 | 2024-05-17 | 广州市丹蓝生物科技有限公司 | 一种储存剂及由其制备的抗体溶液制剂及其应用 |
CN213023169U (zh) * | 2020-08-28 | 2021-04-20 | 东莞东阳光医疗智能器件研发有限公司 | 一种单人份的冻干化学发光试剂免疫试剂管 |
-
2020
- 2020-12-18 CN CN202011500680.5A patent/CN112684167A/zh active Pending
-
2021
- 2021-08-04 EP EP21905068.9A patent/EP4124863A4/en active Pending
- 2021-08-04 WO PCT/CN2021/110438 patent/WO2022127135A1/zh unknown
- 2021-12-17 CN CN202111553600.7A patent/CN114167051B/zh active Active
-
2022
- 2022-10-13 US US17/965,761 patent/US20230048869A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198717A (zh) * | 2014-08-30 | 2014-12-10 | 中国科学院苏州生物医学工程技术研究所 | 一种浓缩葡萄糖检测试剂冻干微球及其制备方法 |
CN110988367A (zh) * | 2019-11-18 | 2020-04-10 | 迈克生物股份有限公司 | 一种贮存剂、用于检测lh的校准品及检测试剂盒 |
CN111965344A (zh) * | 2020-08-25 | 2020-11-20 | 沈阳瑞好生物科技有限公司 | 一种冻干磁微粒化学发光免疫检测试剂盒及其制备方法 |
CN112684167A (zh) * | 2020-12-18 | 2021-04-20 | 安邦(厦门)生物科技有限公司 | 一种化学发光免疫试剂、冻干微球及其及冻干微球的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114167051A (zh) | 2022-03-11 |
EP4124863A4 (en) | 2024-05-29 |
CN112684167A (zh) | 2021-04-20 |
WO2022127135A1 (zh) | 2022-06-23 |
US20230048869A1 (en) | 2023-02-16 |
EP4124863A1 (en) | 2023-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114167051B (zh) | 一种化学发光免疫微球冻干制剂及其制备方法以及应用 | |
KR100749982B1 (ko) | 혈관 내피 성장 인자용 elisa | |
US10472400B2 (en) | Cardiac troponin I ultra-sensitive detection reagent kit, and ultra-sensitive detection method therefor | |
Hattori et al. | Ectopic production of human chorionic gonadotropin in malignant tumors | |
CN104034882B (zh) | 用于测定样本中的待测定成分的方法和试剂盒 | |
WO2016127320A1 (zh) | 一种用于检测胃泌素-17的试剂盒及其制备方法和应用 | |
AU2008222578B2 (en) | Method of determining NT-proBNP | |
JP2002511143A (ja) | Cペプチド特異的アッセイ法 | |
CN107219371A (zh) | Pct荧光微球免疫层析检测试剂卡及其制备方法 | |
EP1619505B1 (en) | Method for the diagnosis of critically ill patients | |
CN112014566A (zh) | 一种氨基末端脑利钠肽前体检测试剂盒、制备方法及用途 | |
CN114113637A (zh) | 一种促甲状腺激素受体抗原试剂及促甲状腺激素受体抗体定量检测试剂盒 | |
CN110646624A (zh) | 一种基质素2的elisa试剂诊断盒及其使用方法 | |
CN110441531B (zh) | 一种检测血液中降钙素原的试剂盒及制备方法 | |
CN104418937B (zh) | 人pgii抗原表位肽、抗原、抗体、用途及试剂盒 | |
CN106124771A (zh) | 一种一步均相cTnT检测试剂盒及其应用 | |
CN113238055A (zh) | 空间邻近化学发光法检测降钙素原的试剂盒及其检测方法和应用 | |
CN104422773A (zh) | 检测人pgi蛋白的荧光免疫层析试纸及其制备方法 | |
CN104422775B (zh) | 联合检测人pgi蛋白和人pgii蛋白的荧光免疫层析试纸及制法 | |
CN112986585A (zh) | 一种降钙素原检测试剂盒、制备方法及用途 | |
CN104418939A (zh) | 人pgi抗原表位肽、抗原、抗体、用途及试剂盒 | |
CN110261619B (zh) | Prkar2b蛋白作为胃癌血清生物标志物的应用及其试剂盒 | |
Hashida et al. | Novel and sensitive noncompetitive enzyme immunoassay (hetero‐two‐site enzyme immunoassay) for α‐human atrial natriuretic peptide in plasma | |
CN118275698A (zh) | 一种心肌肌钙蛋白i免疫层析检测卡、试剂盒及其应用 | |
CN113960306A (zh) | 稳定吖啶酯标识蛋白的试剂及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240617 Address after: 830000 Xinjiang Uygur Autonomous Region Urumqi High tech Zone (Xinshi District) No. 288, West 1st Lane, Hongyang Road, Biopharmaceutical Accelerator Building 3, 202, 302 Patentee after: Anbang (Xinjiang) Biotechnology Co.,Ltd. Country or region after: China Patentee after: ANBIO (XIAMEN) PRODUCTS Inc. Address before: No. 2016, wengjiao West Road, Xinyang street, Haicang District, Xiamen City, Fujian Province, 361000 Patentee before: ANBIO (XIAMEN) PRODUCTS Inc. Country or region before: China |